News
OpenAI said on Oct. 20, 2026, it acquired Orchestra Bio and will combine the team and technology with its Rosalind life-sciences AI platform.
OpenAI said it has acquired Orchestra Bio, a move it says will bring AI-powered operations into life sciences research and development and help biopharma teams accelerate drug development and advance new treatments.
Evidence and context
In its Oct. 20, 2026 announcement, OpenAI said Orchestra Bio’s team and technology will be combined with Rosalind, OpenAI’s life-sciences AI platform. The company did not provide financial terms in the material supplied. The acquisition is positioned around operational workflows in drug development rather than consumer-facing AI products.
Background material supplied with the announcement describes Orchestra Bio as software for biotechnology and pharmaceutical teams that supports study monitoring, timeline tracking, dependency analysis and operational planning through AI agents, while keeping decision-making with humans. A BiotechTV interview published on Aug. 18, 2025 said the company had emerged from stealth with $20 million, though that publication date is not the original financing date. Separately, MBC BioLabs said on Nov. 4, 2025 that it had partnered with Orchestra Bio to support its community of biotech startups.
Orchestra Bio should not be confused with Orchestra BioMed Holdings, the separate Nasdaq-listed medical-device company trading under OBIO. No next catalyst date was supplied in the source material.
Credit: Source link
